The USA’s Evelo Biosciences has entered into a collaboration with Mayo Clinic, a Minnesota-based research center, to advance immuno-microbiome-based therapies for cancer.
The privately-held company will work with the center’s researchers to isolate and characterize cancer-associated bacteria from patient stool samples and tumor biopsies.
This work will contribute to Evelo's cancer-associated bacteria library, a key platform discovery tool for the development of onco-microbials to treat cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze